Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma

BMC Genomics

Volumn 11, Issue 1, 2010, Pages

  Lafferty Whyte, Kyle ^a   Bilsland, Alan ^a   Cairney, Claire J ^a   Hanley, Lorna ^a   Jamieson, Nigel B ^a   Zaffaroni, Nadia ^b   Oien, Karin A ^a   Burns, Sharon ^a   Roffey, Jon ^c   Boyd, Susan M ^d   Keith, W Nicol ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ST JOHN S COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL AGING; CELL DIVISION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LIPOSARCOMA; MELANOMA; MESENCHYMAL STEM CELL; PERITONEUM MESOTHELIOMA; PROGNOSIS; SCORING SYSTEM; SECRETORY PATHWAY; SENESCENCE SCORING; SIGNAL TRANSDUCTION; SURVIVAL TIME; BREAST TUMOR; CLUSTER ANALYSIS; DISEASE COURSE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MESOTHELIOMA; METABOLISM; METHODOLOGY; PATHOLOGY; PERITONEUM TUMOR; SURVIVAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL AGING; CELL LINE, TUMOR; CLUSTER ANALYSIS; DATABASES, GENETIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MESENCHYMAL STEM CELLS; MESOTHELIOMA; PERITONEAL NEOPLASMS; PROGNOSIS; RESEARCH DESIGN; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 77957190130     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-532     Document Type: Article

References (53)

1. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008, 20:150-155. 10.1016/j.ceb.2008.01.007, 18353625.
2. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008, 42:301-334. 10.1146/annurev.genet.41.110306.130350, 18680434.
3. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006, 66:2881-2884. 10.1158/0008-5472.CAN-05-4006, 16540631.
4. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 2008, 76:947-957. 10.1016/j.bcp.2008.06.024, 18657518.
5. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. Embo J 2003, 22:4212-4222. 10.1093/emboj/cdg417, 175806, 12912919.
6. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005, 65:2795-2803. 10.1158/0008-5472.CAN-04-1270, 15805280.
7. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124:1169-1181. 10.1016/j.cell.2006.02.037, 16564011.
8. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346. 10.1016/S0092-8674(02)00734-1, 12015983.
9. Zhang W, Ji W, Yang J, Yang L, Chen W, Zhuang Z. Comparison of global DNA methylation profiles in replicative versus premature senescence. Life Sci 2008, 83:475-480. 10.1016/j.lfs.2008.07.015, 18723031.
10. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995, 92:9363-9367. 10.1073/pnas.92.20.9363, 40985, 7568133.
11. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009, 9:81-94. 10.1038/nrc2560, 19132009.
12. Young AR, Narita M. SASP reflects senescence. EMBO Rep 2009, 10:228-230. 10.1038/embor.2009.22, 2658552, 19218920.
13. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007, 27:2343-2358. 10.1128/MCB.02019-06, 1820509, 17242207.
14. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6:2853-2868. 10.1371/journal.pbio.0060301, 2592359,2592359, 19053174.
15. Jiang H, Schiffer E, Song Z, Wang J, Zurbig P, Thedieck K, Moes S, Bantel H, Saal N, Jantos J, et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci USA 2008, 105:11299-11304. 10.1073/pnas.0801457105, 2516278, 18695223.
16. Reimann M, Lee S, Loddenkemper C, Dorr JR, Tabor V, Aichele P, Stein H, Dorken B, Jenuwein T, Schmitt CA. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010, 17:262-272. 10.1016/j.ccr.2009.12.043, 20227040.
17. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740. 10.1038/nrm2233, 17667954.
18. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006, 6:472-476. 10.1038/nrc1884, 16723993.
19. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008, 27:5975-5987. 10.1038/onc.2008.213, 18711403.
20. Narita M. Cellular senescence and chromatin organisation. Br J Cancer 2007, 96:686-691. 10.1038/sj.bjc.6603636, 2360064, 17311013.
21. Sedivy JM, Banumathy G, Adams PD. Aging by epigenetics--a consequence of chromatin damage?. Exp Cell Res 2008, 314:1909-1917. 10.1016/j.yexcr.2008.02.023, 2464300, 18423606.
22. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, Tavare S, Arakawa S, Shimizu S, Watt FM, Narita M. Autophagy mediates the mitotic senescence transition. Genes Dev 2009, 23:798-803. 10.1101/gad.519709, 2666340, 19279323.
23. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 2005, 8:19-30. 10.1016/j.devcel.2004.10.019, 15621527.
24. Snipstad K, Fenton CG, Kjaeve J, Cui G, Anderssen E, Paulssen RH. New specific molecular targets for radio-chemotherapy of rectal cancer. Mol Oncol 2009, 4:52-64. 10.1016/j.molonc.2009.11.002, 19969511.
25. Troester MA, Hoadley KA, Parker JS, Perou CM. Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environ Health Perspect 2004, 112:1607-1613. 1247657, 15598611.
26. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, Ho AD. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008, 3:e2213. 10.1371/journal.pone.0002213, 2374903, 18493317.
27. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 2005, 4:1018-1029. 10.4161/cbt.4.9.2165, 16251803.
28. Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, Zaffaroni N, Bilsland A, Keith WN. A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 2009, 28:3765-3774. 10.1038/onc.2009.238, 2875172, 19684619.
29. Borczuk AC, Taub RN, Hesdorffer M, Hibshoosh H, Chabot JA, Keohan ML, Alsberry R, Alexis D, Powell CA. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005, 11:3303-3308. 10.1158/1078-0432.CCR-04-1884, 15867227.
30. Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, Nozuka Y, Tamiya S, Tanaka K, Matsuda S, et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 2005, 207:410-421. 10.1002/path.1848, 16177957.
31. Watanabe T, Oda Y, Tamiya S, Kinukawa N, Masuda K, Tsuneyoshi M. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator. Histopathology 2001, 39:187-197. 10.1046/j.1365-2559.2001.01176.x, 11493336.
32. Bilsland AE, Hoare S, Stevenson K, Plumb J, Gomez-Roman N, Cairney C, Burns S, Lafferty-Whyte K, Roffey J, Hammonds T, Keith WN. Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS One 2009, 4:e6459. 10.1371/journal.pone.0006459, 2714081, 19649288.
33. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of Gene Expression Data Using BRB-Array Tools. Cancer Inform 2007, 3:11-17. 2675854, 19455231.
34. Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer 1999, 6:41-44. 10.1677/erc.0.0060041, 10732785.
35. Bu X, Le C, Jia F, Guo X, Zhang L, Zhang B, Wu M, Wei L. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 2008, 7:392-396. 10.4161/cbt.7.3.5366, 18075305.
36. Sliwinska MA, Mosieniak G, Wolanin K, Babik A, Piwocka K, Magalska A, Szczepanowska J, Fronk J, Sikora E. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech Ageing Dev 2009, 130:24-32. 10.1016/j.mad.2008.04.011, 18538372.
37. Britt-Compton B, Rowson J, Locke M, Mackenzie I, Kipling D, Baird DM. Structural stability and chromosome-specific telomere length is governed by cis-acting determinants in humans. Hum Mol Genet 2006, 15:725-733. 10.1093/hmg/ddi486, 16421168.
38. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, Wappler I, Birket MJ, Harold G, Schaeuble K, et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 2007, 5:e110. 10.1371/journal.pbio.0050110, 1858712,1858712, 17472436.
39. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002, 27:339-344. 10.1016/S0968-0004(02)02110-2, 12114022.
40. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009, 11:973-979. 10.1038/ncb1909, 2743561, 19597488.
41. Pahl MV, Vaziri ND, Yuan J, Adler SG. Upregulation of Monocyte/Macrophage HGFIN (Gpnmb/Osteoactivin) Expression in End-Stage Renal Disease. Clin J Am Soc Nephrol 2009, 5:56-61. 10.2215/CJN.03390509, 19833906.
42. Sheng MH, Wergedal JE, Mohan S, Lau KH. Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Lett 2008, 582:1451-1458. 10.1016/j.febslet.2008.03.030, 18381073.
43. Degerman S, Siwicki JK, Osterman P, Lafferty-Whyte K, Keith WN, Roos G. Telomerase upregulation is a postcrisis event during senescence bypass and immortalization of two Nijmegen breakage syndrome T cell cultures. Aging Cell 9:220-235. 10.1111/j.1474-9726.2010.00550.x, 20089118.
44. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000, 24:236-244. 10.1038/73439, 10700175.
45. Lafferty-Whyte K, Bilsland A, Hoare SF, Burns S, Zaffaroni N, Cairney CJ, Keith WN. TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia 2010, 12:405-414. 2864478, 20454512.
46. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031. 10.1016/j.cell.2008.03.039, 18555778.
47. Roxburgh CSD, Salmond JM, Horgan PG, Oien KA, McMillan DC. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. European Journal of Cancer 2009,
48. Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE, Gewirtz DA. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol 2005, 81:445-458. 10.1080/09553000500168549, 16308915.
49. Quick QA, Gewirtz DA. An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells. J Neurosurg 2006, 105:111-118. 10.3171/jns.2006.105.1.111, 16871885.
50. Bennett DC. How to make a melanoma: what do we know of the primary clonal events?. Pigment Cell Melanoma Res 2008, 21:27-38. 10.1111/j.1755-148X.2007.00433.x, 18353141.
51. Maldonado AG, Doucet JP, Petitjean M, Fan BT. Molecular similarity and diversity in chemoinformatics: from theory to applications. Mol Divers 2006, 10:39-79. 10.1007/s11030-006-8697-1, 16404528.
52. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN. High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 2008, 98:1467-1474. 10.1038/sj.bjc.6604328, 2361713, 18414473.
53. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, Baratti D, Deraco M, Costa A, et al. Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. Clin Cancer Res 2008, 14:4134-4140. 10.1158/1078-0432.CCR-08-0099, 18593991.